NCT06966856View on ClinicalTrials.gov

This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcting Early-onset Vitamin B12 Deficiency in Adult Patients Using Proton Pump Inhibitors (PPIs). The Primary Outcome is the Change in Serum Vitamin B12 Levels Over a 6-week

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 30, 2026

Primary Completion Date

December 30, 2028

Study Completion Date

December 30, 2029

Conditions
Hypovitaminosis b 12
Interventions
DRUG

Cyanocobalamin 1000 Mcg Oral Tablet

Oral cyanocobalamin supplement administered as a 1000 mcg tablet taken once daily for 6 weeks. Used in patients with early-onset B12 deficiency during PPI therapy.

DRUG

Cyanocobalamin 1000 Mcg Sublingual Tablet

Sublingual cyanocobalamin supplement administered as a 1000 mcg tablet placed under the tongue once daily for 6 weeks. Used in patients with early-onset B12 deficiency during PPI therapy.

OTHER

Proton Pump Inhibitor therapy only

This group will continue their standard PPI therapy without receiving any vitamin B12 supplementation, serving as a control group for the comparison of B12 correction efficacy.

All Listed Sponsors
lead

Tanta University

OTHER